Creatinolfosfate
- Generic Name
- Creatinolfosfate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C4H12N3O4P
- CAS Number
- 6903-79-3
- Unique Ingredient Identifier
- 5O564RN1QD
- Background
COP is under investigation for the treatment of Rheumatoid Arthritis, Mature B-Cell Lymphoma, and Noninflammatory Degenerative Joint Disease. COP has been investigated for the treatment of Diabetic Retinopathy.
- Associated Conditions
- -
- Associated Therapies
- -
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 504
- Registration Number
- NCT06072131
- Locations
- 🇪🇸
Hospital del Mar Medical Research Institute, Barcelona, Spain
🇪🇸Hospital Universitario y Politecnico La Fe, Valencia, Spain
🇺🇸University of California, San Francisco Fresno, Clovis, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath